Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report)'s stock price traded down 5.2% on Friday . The company traded as low as $17.20 and last traded at $16.41. 64,457 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 173,042 shares. The stock had previously closed at $17.31.
Analyst Upgrades and Downgrades
Separately, Oppenheimer assumed coverage on Pulse Biosciences in a research note on Monday, July 7th. They issued an "outperform" rating and a $22.00 target price for the company. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $22.00.
View Our Latest Report on Pulse Biosciences
Pulse Biosciences Stock Up 0.6%
The business has a fifty day moving average of $15.39 and a 200 day moving average of $16.87. The firm has a market cap of $1.07 billion, a P/E ratio of -15.19 and a beta of 1.60.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02).
Insider Activity
In other Pulse Biosciences news, CTO Darrin Uecker sold 15,000 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $16.40, for a total value of $246,000.00. Following the completion of the sale, the chief technology officer directly owned 137,872 shares in the company, valued at $2,261,100.80. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 71.50% of the stock is owned by company insiders.
Hedge Funds Weigh In On Pulse Biosciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Pulse Biosciences by 98.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock worth $29,000 after buying an additional 838 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after buying an additional 2,156 shares during the last quarter. AlphaQuest LLC lifted its stake in Pulse Biosciences by 68.0% in the 1st quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after acquiring an additional 1,261 shares in the last quarter. Finally, PNC Financial Services Group Inc. bought a new stake in Pulse Biosciences in the 1st quarter valued at approximately $90,000. 76.95% of the stock is owned by institutional investors and hedge funds.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
